Among 563 screened patients , 75 ( 13.3 % ) were Her2 positive ( IHC 2 + / 3 + and FISH + ) and 61 met all eligibility criteria ( median age , 64 years ; 54/61 males ; 50/61 baseline ECOG-PS 0-1 ; 11 locally advanced and 50 metastatic ) .